Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).

Summary

The purpose of this study is to determine whether Bendamustine in combination with Etoposide, Cytarabine and Melphalan (BeEAM) are effective as conditioning followed by ASCT in patients with aggressive lymphoma.

Conditions

• Bendamustine
• Conditioning Therapy
• Autologous Stem Cell Transplant
• Aggressive Non Hodgkin's Lymphoma

Interventions

DRUG

Bendamustine-EAM

Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1

Sponsors & Collaborators

• Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

  lead OTHER

Principal Investigators

• Mª Dolores Caballero, MD · University of Salamanca

• Alejandro Martín, MD · University of Salamanca

• Javier Briones, MD · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

• Juan Manuel Sancho, MD · Germans Trias i Pujol Hospital

• Cristina Barrenetxea, MD · Hospital Vall d'Hebrón

• Javier López, MD · Hospital Universitario Ramon y Cajal

• Mª José Rodríguez, MD · Hospital Universitario de Canarias

• Jorge Gayoso, MD · Gregorio Marañón Hospital

• Miguel Ángel Canales, MD · Hospital Universitario La Paz

• Carlos Grande, MD · Hospital Universitario 12 de Octubre

• Isidro Jarque, MD · Hospital La Fe

• José Rifón, MD · Clínica Universitaria Navarra

• Andres Sánchez, MD · Hospital Virgen de la Arrixaca

• Cristina Castilla, MD · Hospital Morales Meseguer

• José Luis Bello, MD · Complejo Hospitalario Universitario de Santiago de Compostela

• Armando López, MD · Hospial Clínic de Barcelona

• Eulogio Conde, MD · Hospital Marqués de Valdecilla

• Reyes Arranz, MD · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

• Encarnación Monzó, MD · Hospital Arnau de Vilanova de Valencia

• Rosario Varela, MD · Complejo Hospitalario Universitario de A Coruña

• Mª José Ramírez, MD · Hospital Jerez de la Frontera

• Fátima de la Cruz, MD · Hospital Virgen del Rocío

• Ana Pilar González, MD · Hospital Central de Asturias

• Luis Palomera, MD · Hospital Clínico de Zaragoza "Lozano Blesa"

• Raquel del Campo, MD · Hospital Son Llátzer

• Mª José Terol, MD · Hospital Clínico de Valencia

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2011-05-31

Primary Completion

2015-11-30

Completion

2015-11-30

Countries

• Spain

Study Locations